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Splanchnic Haemodynamics and Vasoactive
Agents an Experimental Cirrhosis
J. G. GERAGHTY, W. J. ANGERSON and D. C. CARTER
University Department of Surgery, Royal Infirmary, Glasgow, U.K.
It’is well known that portal hypertension is associated with a hyperdynamic systemic circulatory
state. This study measures systemic and splanchnic haemodynamics in an experimental rat
model ofhepatic cirrhosis. It also investigates the association between haemodynamic changes in
cirrhotic animals and circulating levels of the vasoactive hormones glucagon and vasoactive
intestinal polypeptide (VIP). Splanchnic blood flow was significantly increased in the cirrhotic
group (13.2 + 1.3 vs. 9.2 1.6 ml/min, P < 0.05). Circulating levels ofglucagon andVIP were two
and five fold increased respectively in cirrhotic animals compared to controls. There was a strong
correlation between portal pressure and glucagon levels in the cirrhotic group (r 0.85). Raised
splanchnic blood flow is partly responsible for elevated portal pressure in this model and this rise
may be humorally mediated.
INTRODUCTION
It has been well established that portal hypertension
is associated with hyperdynamic systemic and splan-
chnic circulatory states 1’2. It has also been demon-
strated that raised splanchnic blood flow plays an
important role in the maintenance of a chronically
elevated portal pressure in experimental portal hyper-
tension3’’. Several theories have been proposed to
explain the splanchnic hyperaemia observed in portal
hypertension including decreased sensitivity of splan-
chnic arterioles to noradrenaline5 and the opening of
intestinal arteriovenous shunts6. It has also been sug-
gested that circulating vasoactive agents, normally
catabolised by the liver, are present in increased quan-
tities in hepatic cirrhosis and may mediate these
haemodynamic changes 7. Glucagon, a potent intesti-
nal vasodilator, is present in increased concentration in
the plasma of patients and animals with portal hyper-
tension and has been implicated in the intestinal hy-
peraemia associated with this conditiona-l. The
present study defines the systemic and splanchnic
haemodynamics changes in an animal model ofexperi-
mental cirrhosis, and assesses their relationships with
circulating concentration of putative splanchnic vaso-
dilators (glucagon and vasoactive intestinal peptide).
MATERIALS AND METHODS
Male Sprague-Dawley rats (Bantin and Kingman Ltd.
UK) were housed in a controlled environment with
a 12-hour light: dark cycle. They were fed standard rat
diet but were fasted overnight in wire bottom cages
prior to measurement of splanchnic haemodynamics.
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Production of Experimental Cirrhosis
Hepatic cirrhosis was produced using oral administra-
tion of carbon tetrachloride (CC14) as previously de-
scribed11. Animals weighing 150 +__ 20gm were given
phenobarbitol (150/100ml) in their drinking water to
induce the enzyme cytochrome P450 which has been
shown to increase rat liver sensitivity to CCI, 12. This
hepatotoxin was given once weekly using an orogastric
tube under light ether anaesthesia. The initial dose was
0.15ml and each subsequent weekly dose was cal-
culated according to the animals weight loss following
the previous dose. Carbon tetrachloride was stopped
as soon as ascites developed and experiments were
performed 3 weeks later. Control animals of similar
weight also received phenobarbitol by weekly gavage
under ether anaesthesia and were weighed daily; how-
ever they did not receive carbon tetrachloride.We have84 J.G. GERAGHTY et al.
previously found 11 that40% ofanimals receiving CC14
as described above will develop ascites and micro-
nodular hepatic cirrhosis (Figure 1). A total of 15 ani-
mals were gavaged With CC14 and the six animals
which developed ascites in this group had haemo-
dynamic experiments performed.
Surgical Preparation,
Systemic and splanchnic haemodynamics were meas-
ured using a reference microsphere sample tech-
nique13. Each animal had a tracheostomy performed
and was ventilated using a Harvard rat ventilator
(model 68) with a 2:1 nitrous oxide--oxygen mixture
in 0.5% halothane. The femoral artery was cannulated
on both sides and mean arterial pressure recorded
using a strain gauge transducer connected to a Gould
8000 semi-dual recorder. Arterial blood gas concentra-
tions were analysed (ABL, Radiometer) and only ani-
mals with a P02 over 90mmHg, a PC02 in the range
35-42mmHg and apH greater than 7.35 were included
in the study. Rectal temperature was monitored and
kept at 37__+0.5C by means of a heat lamp. The
abdomen was opened using a midline incision and
a cannula inserted into the ileocolic branch of the
portal vein to measure portal venous pressure. The
abdomen was closed and portal pressure measured
a minimum of 30 minutes later and only when a respir-
atory pattern was present on portal venous tracing.
Mean arterial and portal pressure measurements were
taken simultaneously. Finally a cannula was inserted
into the left ventricle via the right carotid artery for
injection of radio-labelled microspheres. Insertion was
performed under continuous pressure monitoring and
correct positioning was verified both by the presence
of a ventricular pattern on pressure recording and
by checking the position of the tip of the cannula at
the end of the experiment.
Haemodynamic Measurements
Once the animal was haemodynamically stable and
pressure measurements had been recorded, approxi-
mately 100,000 Ruthenium-labelled microspheres were
injected into the left ventricle over 25 seconds 13. The
microspheres were suspended in 10% Dextran with
a drop of 0.01% "Tween" 80 added to prevent clump-
ing. The amount of radioactivity in the injection sy-
ringe (volume 0.2ml) was measured in a gamma-
scintillation counter (Packard 5000) and the syringe
was vortexed for 30 seconds prior to injection. Arterial
pressure was recorded continuously during infusion
and a change in pressure ofmore than 10% over basal
value led to automatic exclusion.
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The femoral artery cannula was connected to a
peripheral 2 ml syringe, which was attached to a with-
drawal pump (Sage Instruments). Withdrawal was
commenced 10 seconds before intra-ventricular injec-
tion ofmicrospheres and stopped 60 seconds later. The
reference sample in the syringe therefore served as an
"artificial organ" with a known blood flow (1 ml/min).
The radioactivity in the syringe was counted in
a gamma-scintillation counter. The degree of portasy-
stemic shunting was measured by injecting 100,000
Tn-labelled microspheres into the ileocolic branch of
the portal vein as previously described14. The animal
was killed 2 minutes later and the lungs, liver, splan-
chnic organs and kidneys were removed and placed in
vials for measurement of radioactivity.
Calculations
Cardiac output (ml/min)
Injected radioactivity (dpm)x Reference organ flow (ml/min)
Reference organ radioactivity (dpm)
Organ blood flow (ml/min)
Organ radioactivity (dpm)x Reference organ flow (ml/min)
Reference organ radioactivity (dpm)
Portal venous inflow was the sum of flows to the
stomach, spleen, small and large bowel, and mesentery.
Vascular resistance (mm Hg/ml/min)
Change in pressure across vascular bed (mm Hg)
Blood flow to vascular bed (ml/min)
Portasystemic Shunting (%)
Lung radioactivity (dpm)
x 100
Liver + lung radioactivity (dpm)
Uniform mixing of microspheres in blood was check-
ed by comparing radioactivity in both kidneys and
animals with a greater than 10% difference were
excluded.
Measurement of Glucagon and VIP
At the end of the experiment blood was taken from the
inferior vena cava for measurement of glucagon and
vasoactive intestinal polypeptide levels. Each sample
was placed in a heparinised tube and frozen. A radio-
immunoassay technique was used to measure glucagon
and vasoactive intestinal polypeptide15,16.
Statistical Analysis
Results are presented as mean __+ standard error of the
mean (mean + SEM).The statistical tests used are the
Mann-Whitney ind Pearsons correlation coefficient.
RESULTS
Systemic and splanchnic haemodynamics
Portal venous pressure was significantly higher in
cirrhotic animals compared to controls (Table 1).
Portasystemic shunting was not detectable in controls
but 23.4% portal blood was diverted into the
systemic circulation in cirrhotic animals.
Portal hypertension was associated with a rise in
cardiac output and reduced total portal resistance
(Table 1). There was a significant rise in splanchnic
blood flow which was associated with a reduction in
splanchnic arteriolar resistance. Total portal resistance
was 50% greater in cirrhotic animals but this difference
compared to controls was not statistically significant.
Hormonal Concentrations
There was a five fold increase in the level of vasoactive
intestinal polypeptide in the cirrhotic group compared
to controls (Table 2). However there was no correla-
tion between portal pressure and levels of vasoactive
intestinal polypeptide in cirrhotic animals. Although
glucagon levels were not significantly increased in
cirrhotic animals (Table 2) there was a strong correla-
tion (r=0.85) between portal venous pressure and
glucagon levels (Figure 2). There was no correlation
between glucagon levels and the magnitude of porta-
systemic shunting.
Table 1 Haemodynamic comparison between cirrhotic and con-
trol groups.
Cirrhosis Control
(n 6) (n 6)
Portal pressure (mmHg) 15.8 +/- 1.4 6.4 + 0.3
Portasystemic shunting (%) 23.4 +/- 3.2 0
Cardiac output (ml/min) 172.5 45.4 116.7 + 20.9
Total peripheral (mmHg/ml/min) 1.1 +/- 0.1 1.7 +/- 0.2*
resistance
Splanchnic inflow (ml/min) 13.2 1.3 9.2 + 1.6"
Splanchnic arteriolar (mmHg/ml/min) 8.0 + 1.3 15.1 +/- 3.1"
resistance
Total portal resistance (mmHg/ml/min) 1.2 + 0.1 0.8 0.1"
Values are mean +/- SEM; * p < 0.0186 J.G. GERAGHTY et al.
Table 2 Hormonal levels in cirrhotic and control groups.
Cirrhosis Control
(n 6) (n 6) p-value
Glucagon (ng/L) 865 + 135
Vasoactive intestinal
polypeptide (ng/L) 150 + 32
Values are mean SEM
481 152 0.09
31 + 17 0.01
DISCUSSION
This study shows that experimental cirrhosis is asso-
ciated with hyperdynamic systemic and splanchnic
circulatory states. These results are in agreement with
previous observations that raised splanchnic inflow is
the primary factor in the maintenance of an elevated
portal pressure in experimental portal hyperten-
sion 1’2’3. It has been suggested that this rise in splan-
chnic inflow may be hormonally mediatedT. Glucagon
and vasoactive intestinal polypeptide are known to
increase splanchnic blood flow. These hormones are
produced by splanchnic organs and are normally
catabolised by the liver. In portal hypertension how-
ever, glucagon and vasoactive intestinal polypeptide
may escape into the systemic circulation via portasy-
stemic collateral vessels.
The second aim of the present study therefore was to
measure the levels of glucagon and vasoactive intes-
tinal peptide in portal hypertension and to establish
whether they were associated with the rise in portal
pressure seen in experimental cirrhosis. The results
show that both glucagon and vasoactive intestinal
polypeptide levels are increased in experimental cirr-
hosis. They also demonstrate a strong correlation be-
tween portal pressure and glucagon levels suggesting
that this agent may be responsible in part for the rise in
portal pressure seen in cirrhotic animals. In contrast
there was no association between circulating levels of
vasoactive intestinal polypeptide and portal venous
pressure. It is not clear why these hormones are raised
in the model of cirrhosis. One possible mechanism is
that they pass directly into the systemic circulation in
portasystemic collateral vessels and therefore escape
catabolism in the liver. There was however no correla-
tion between circulating levels of glucagon and the
magnitude of portasystemic shunting seen in animals
with cirrhosis. Portasystemic collateral vessels are only
partly responsible however for physiological shunting
in portal hypertension. Reduced catabolism of sub-
stances normally degraded by the liver will also give
rise to physiological shunting in hepatic cirrhosis. It is
possible that the rise in glucagon levels in portal hyper-
tensive animals in the present study may be due in part
to reduced catabolism by a cirrhotic liver. Pancreatic
hypersecretion of glucagon is known to occur in ex-
perimental portal hypertension and this could have
also contributed to the raised glucagon levels observed
in the present study17.
There is now strong experimental evidence to sug-
gest that humoral factors mediate the splanchnic hy-
peraemia seen in chronic prehepatic portal hyper-
tension. It has been shown that cross-perfusion of the
mesenteric circulation of normal rats with arterial
blood from rats with portal hypertension results in
a 30% increase in intestinal blood flow.
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Figure 2 There was a strong correlation between glucagon levels and portal pressure measurements in cirrhotic animals.HAEMODYNAMICS AND VASOACTIVE AGENTS IN EXPERIMENTAL CIRRHOSIS 87
Recent studies have concentrated on the role of
glucagon as a possible mediator of this response as it
reduces intestinal arteriolar resistance and levels are
known to be elevated in the plasma of patients and
animals with portal hypertensions’9. This hypothesis
was tested by Benoit and colleagues1 who showed
that administration of glucagon antiserum caused
a 30% reduction in portal venous inflow in rats with
portal hypertension.
The present study differs from previous studies in
that it measures splanchnic haemodynamics, glucagon
and vasoactive intestinal polypeptide levels, and portal
venous pressure in experimental cirrhosis. The results
support the contention of Benoit et al. that glucagon
plays a role in the maintenance of a raised portal
pressure in portal hypertension7,t. Given that resis-
tance to portal blood flow also plays a role in elevating
portal pressure, it is likely that there is a synergistic
effect between increased portal venous inflow and
resistance to flow resulting in portal hypertension.
Raised portal pressure in hepatic cirrhosis could there-
fore be explained by the following sequence of events.
As cirrhosis develops, portal pressure rises and beyond
a critical pressure portasystemic collateral vessels
open. Humoral agents such as glucagon are released
into the systemic circulation through these shunts
giving rise to a reduction in splanchnic arteriolar resis-
tance. The resulting increase in splanchnic blood flow
then produces a rise in portal venous pressure. The
evidence supporting this hypothesis however is limited
almost exclusively to animal studies. Similar experi-
ments in humans are difficult to perform because ofthe
lack ofestablished non-invasive techniques to measure
splanchnic blood flow, magnitude of portasystemic
shunting and portal venous pressure. The present
study suggests that glucagon may play a role in the
maintenance of raised portal pressure but this hypo-
thesis needs to be tested in a clinical setting.
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INVITED COMMENTARY
Several years ago, we proposed a relationship between
portosystemic shunting, glucagon and the hemo-
dynamic consequences of chronic portal hypertension.
The essence of our hypothesis was that portosystemic
shunting led to increased circulating levels ofglucagon
which began to act as a dilator of the splanchnic
vasculature. As a result, the hyperdynamic splanchnic
circulation developed. In the years since this initial
report, several studies have examined the role of hu-
moral factors in portal hypertensive conditions. The
work of Geraghty et al., joins a growing body of
literature supporting the role ofglucagon as a mediator
of the hemodynamic derangements in chronic portal
hypertension. A major finding ofthe present study was
a correlation between portal pressure and glucagon88 J.G. GERAGHTY et al.
levels in cirrhotic rats. The authors suggested that
glucagon may mediate the increased portal pressure.
There are two possible mechanisms by which glueagon
could raise portal pressure: 1) increased portal venous
inflow and 2) increased portal vascular resistance.
Previous reports from our laboratory have clearly
shown that glucagon is capable of increasing portal
venous inflow in chronic portal hypertension. Further-
more, we have suggested that the increased portal
inflow can account for a significant portion of the rise
in portal venous pressure observed in prehepatic portal
hypertension. Thus it is conceivable that the correla-
tion between glucagon and portal pressure represents
active congestion of the portal system, a result of the
splanchnic vasodilation. An alternative explanation
for glucagon induced changes in portal pressure could
be related to the known action of glucagon on the
hepatic portal system. Richardson and Withrington
reported a significant correlation between portal
glucagon concentrations and increased portal vascular
resistance in normal dogs. Superior mesenteric vascu-
lar flow increased and hepatic arterial vascular resis-
tance was unaltered during glucagon infusion. These
data lead us to suggest that glucagon may augment
portal pressure in cirrhosis by selectively constricting
the hepatic portal circulation. To this end, the in-
creased portal resistance observed by Geraghty et al.,
may have also been related to glucagon. However,
neither of the aforementioned mechanisms can be
directly supported by the data presented by these
investigations.
In summary, Geraghty et al., propose a role for
glucagon as a mediator of the portal hypertension
associated with cirrhosis. Data in the literature would
lead one to conclude that both increased portal venous
inflow and increased hepatic portal resistance are con-
sequences of the hyperglucagonemia of cirrhosis. Fu-
ture studies by these investigators will be necessary
before they can advance their hypothesis.
Joseph N. Benoit, Ph.D.
Zhi-Yong Wu, M.D., Ph.D.
Department of Physiology and Biophysics
Louisiana State University Medical Center
Shreveport, LA 7113-3932
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